Standard News

Hide Advertisement
  • Business
  • Culture
  • News
  • Technology
  • Trending
Site logo
ADVERTISEMENT
ADVERTISEMENT

DuPont ordered to pay $5.1 million in trial over Teflon-making chemical

By Reuters 2 min read
A view of the Dupont logo on a sign at the Dupont Chestnut Run Plaza facility near Wilmington, Delaware

By Jessica Dye

NEW YORK (Reuters) – A U.S. jury on Wednesday ordered DuPont to pay $5.1 million to a man who said he developed testicular cancer from exposure to a toxic chemical used to make Teflon at one of its plants, according to a DuPont spokesman.

Advertisement

It is the second time jurors in Ohio federal court have found against DuPont, which is facing more than 3,400 lawsuits from residents who say they contracted one of six diseases linked to perfluorooctanoic acid, known as PFOA or C-8, which is used to make products such as Teflon non-stick cookware.

Following a five-week trial, jurors deliberated for less than a day before finding DuPont was negligent and awarding $5.1 million in compensatory damages to David Freeman, an Ohio resident who said he developed testicular cancer from his exposure to C-8 in drinking water.

The jury also decided that DuPont had acted with actual malice, a finding that exposes the company to punitive damages, the amount of which will be determined at a proceeding starting Thursday.

A DuPont spokesman declined to comment. While DuPont is the named defendant, a recent spin-off of its performance chemicals segment, Chemours Co, will cover its liability.

A spokeswoman for Chemours, Cynthia Salitsky, said the verdict will be appealed. To the extent DuPont claims indemnification for the verdict, “Chemours retains its defenses to such claims,” she said in a statement.

Lawyers for Freeman did not immediately return a request for comment. The trial was a so-called bellwether, the verdict of which is intended to help the companies and plaintiffs value remaining cases alleging similar facts.

The first trial over C-8 exposure resulted in a $1.6 million verdict and no punitive damages last year.

Chemours shares closed down 22.5 percent at $5.93 in heavy volume. DuPont shares ended down 1.8 percent at $61.85 per share.

(Reporting by Jessica Dye; Additional reporting by Lewis Krauskopf; Editing by Chris Reese)

tagreuters.com2016binary_LYNXNPEC651IF-VIEWIMAGE

Advertisement - Continue reading below

Dutch Designer Mirjam de Bruijn Makes Eco-Friendly Products ‘Attractive’
Business
Sierra McCleary-Harris 3 min read

Dutch Designer Mirjam de Bruijn Makes Eco-Friendly Products ‘Attractive’

Judge leans Redstone’s way in trial over media mogul’s mental state
News
Reuters 4 min read

Judge leans Redstone’s way in trial over media mogul’s mental state

-fare carrier

SFO has seen a decrease in its low-fare airline services
Travel
Greg Fischer 4 min read

-fare carrier SFO has seen a decrease in its low-fare airline services

U.S. government shifts $81 million to Zika vaccine research
News
Reuters 3 min read

U.S. government shifts $81 million to Zika vaccine research

Detroit teachers expected back in class after pay assurances: union
News
Reuters 2 min read

Detroit teachers expected back in class after pay assurances: union

Tornadoes and storms hit U.S. Great Plains, injure two in Kansas
News
Reuters 2 min read

Tornadoes and storms hit U.S. Great Plains, injure two in Kansas

Ex-FBI agent admits lying during ‘Whitey’ Bulger trial
News
Reuters 2 min read

Ex-FBI agent admits lying during ‘Whitey’ Bulger trial

Trump calls for increased military response after Orlando shooting
News
Reuters 1 min read

Trump calls for increased military response after Orlando shooting

Sept. 11 suspects’ treatment a focus in Guantanamo hearing
News
Reuters 2 min read

Sept. 11 suspects’ treatment a focus in Guantanamo hearing

Flying pigs and prisms: Pink Floyd expo to open at London’s V&A
Entertainment
Reuters 2 min read

Flying pigs and prisms: Pink Floyd expo to open at London’s V&A

load more Loading posts...

sidebar

ADVERTISEMENT
ADVERTISEMENT

sidebar-alt

  • About Us
  • Imprint
  • Contact Us
  • Terms of Service
  • Privacy Policy